← Eichor
Study identifier: NCT07433946 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Partial Enteral Nutrition to Prevent Weight Loss and Sarcopenia in IBD Patients at Nutritional Risk - SIMBA

Condition: Ulcerative Colitis (Disorder) · Crohn Disease · Malnutrition or Risk of Malnutrition  ·  Sponsor: Lionhealth Srl Società Benefit

PhaseNA
Planned participants146
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This is a multicenter, open-label, randomized two-arm interventional nutritional study evaluating the effects of partial enteral nutrition (LH VIOLA) in patients with Inflammatory Bowel Disease (IBD) at risk of malnutrition. A total of 146 patients (73 per arm) will be enrolled across 4 centers. IBD, including Crohn's Disease and Ulcerative Colitis, is associated with malabsorption, weight loss, sarcopenia, and malnutrition, which negatively impact quality of life and treatment outcomes. Nutritional assessment using the Malnutrition Universal Screening Tool (MUST) will identify patients at risk. Participants will be randomized to receive either nutritional counseling alone or counseling plus oral LH VIOLA supplementation (≥412 kcal/day) for 16 weeks. The primary objective is to evaluate maintenance or recovery of body weight at 16 weeks. Secondary objectives include assessment of weight at 24 weeks, muscle strength (handgrip), body composition and metabolic parameters (BIA/BIVA, vitamin B12/D, pre-albumin), quality of life (SF-12), economic impact, adherence, gastrointestinal tolerability, and reduction in malnutrition risk (MUST score). The study duration per patient is 24 weeks (16 weeks of intervention plus 8 weeks follow-up), with a total study duration of 18 months. The sample size is powered to detect an increase from 40% to 65% in patients achieving weight maintenance or gain at 16 weeks, accounting for a 15% dropout rate.

This description comes directly from the study's public registry record.

Talk to the study team

Roberta Majer, Pharmaceutical Chemistry and T  ·  +39 3357664333  ·  studiclinici@lionhealth.tech

Lucio Vitiello, Biological Sciences  ·  +39 3331756863  ·  vitiello@lionhealth.tech

Always discuss trial participation with your own doctor first.

Locations (4)

IRCCS HumanitasRozzano, Milano, ItalyRecruiting
AOU Federico IINaples, ItalyRecruiting
IRCCS Policlinico San Matteo - PaviaPavia, ItalyRecruiting
Ospedale Isola Tiberina - Gemelli IsolaRoma, ItalyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07433946